Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00469352 · ClinicalTrials.gov registry record · Phase 3
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
A Phase 3 study of Macular Degeneration, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00469352: Completed Phase 3 study of Macular Degeneration, sponsored by Oregon Health and Science University.
NCT00469352 is a Phase 3 study of Macular Degeneration that has completed, run by Oregon Health and Science University. The registered enrollment target is 150 participants, below the 173-participant average among 26 other Macular Degeneration trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00469352, a Phase 3 study of Macular Degeneration, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand whether genes or certain factors in the environment determine how eyes will respond to Lucentis (ranibizumab) treatment. For example, whether having variants within specific genes means that a patient is likely to get better vision from treatment than another patient with different genes.
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (1)
Oregon
- Casey Eye Institute, Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
What the finished NCT00469352 record still lists
NCT00469352 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 173-participant average among 26 other Macular Degeneration trials with a reported enrollment target (13% lower).
The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT00469352 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT00469352 about?
NCT00469352 is a clinical study titled "A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD". The purpose of this study is to understand whether genes or certain factors in the environment determine how eyes will respond to Lucentis (ranibizumab) treatment. For example, whether having variants within specific genes means that a patient is likely to get better vision from treatment than anoth...
What is the current status of trial NCT00469352?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2007-05. Estimated completion is 2010-04.
What conditions does trial NCT00469352 study?
This clinical trial studies the following conditions: Macular Degeneration.
What interventions are being tested in trial NCT00469352?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00469352?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00469352 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00469352's enrollment target sits among peer trials
150 9th of 26 higher than 18 of 26 other Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
COMPLETED · Phase 3
-
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
COMPLETED · Phase 3
-
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
COMPLETED · Phase 3
-
Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
COMPLETED · Phase 3
-
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
COMPLETED · Phase 3
-
Factors in Learning And Plasticity: Macular Degeneration
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia